The Manila Times

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a ...
MPR

Cosentyx Indication Expanded to Include Pediatric Hidradenitis Suppurativa

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

Novartis Pharma AG: Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagn ...
Hosted on MSN

Report: Oregon Youth Authority director knew of issues with abuse investigations for years

Oregon Youth Authority Director Joe O'Leary was unwilling or unable to manage the agency office tasked with investigating complaints of abuse for years and systemic failures in the office posed a ...

Pearson airport therapy dogs bring comfort to stressed travellers

Kaula, Brandy and Bram from St. John Ambulance are therapy dogs spreading smiles and calm at Pearson Airport on one of the busiest travel days of the year.